Icon
+91 94997 68112
Login Register

Xywav - (0.234 g/0.096 g/ 013 g/0.04 g per mL)

Calcium Oxybate, Magnesium Oxybate, Potassium Oxybate and Sodium Oxybate Jazz Pharma
0.234 g/0.096 g/ 013 g/0.04 g per mL
Less Than $1000 mn
Less Than 5
Less Than 5
None
Less Than 5
None None
XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy
Yes
**** ****** **** ***** (***) ** **** **, **** ** ******* ’***, '***, ’***, ’***, ’***, ’***, ’***, ’***, ’*** *** ’***. *** *********** ** **** ******* ****** ** *** ****. **, ** ****** **** ******** **** ****** *** ******* ***** *** ****. *** ****** **** - *****://********.**********.***/****/*****/**** - *** ********** ***** ***** ** ****** **** *********** *** ***** ** ** ** ******* ****, ********* ********** *********** ** ****** ****.
Xywav Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14
***** **** ** **** **, **** *** ********* **** ** **** **, **** **** ** **** **, **** **** ** **** **, **** **** ** **** **, **** **** ** **** **, **** **** ** **** **, **** **** ** **** **, **** **** ** **** **, **** **** ** **** **, **** **** ** *** **, **** (***** ******) **** ** *** **, **** **** ** *** **, ****
**** **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ***\ ********* *** **, **** ******* ********* ******** ***** *** **** (***)
**** ** \ ** *** **, **** ******* **** ***** *** **** (***)
  1. *** **, **** : * **** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : **** ****** **** ***** ** ******* ’***, '***, ’***, ’***, ’***, ’***, ’***, ’***, ’*** *** ’*** ******* ***** **** *** ***** ** ***** **, ****. ***** **** **** ** *** ********** *** ** ****** ****.
  3. *** **, **** : **** **** ***** ** * ***** ****** ****** '*** ******** ** ***** **, ****.
  4. *** **, **** : **** ***** * *** **** ******* ***** **** ***** ****** ******* '*** *** '***
  5. *** *, **** : **** ******** **** ** ***** ****-** ****** **** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, '*** *** ’***
  6. *** **, **** : **** **** **** **** ************ ** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, '*** *** ’***

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.